Tirzepatide, a novel twincretin drug, significantly improves weight loss and glycemic control in obese and type 2 diabetes patients, outperforming traditional treatments in clinical trials.

A post hoc analysis of the SRMOUNT-1 study finds weight loss from the use of tirzepatide was associated with strong benefits ...

Some patients fear tirzepatide, sold by Eli Lilly under the brand names Zepbound and Mounjaro, will be hard to get and prohibitively expensive once compounding pharmacies are no longer producing it.

Adults with type 2 diabetes receiving tirzepatide had significantly greater declines in urine albumin-to-creatinine ratio than those receiving comparators such as placebo or another therapy ...

About 82% of participants taking tirzepatide experienced 5% or greater weight loss. In comparison, only 66.5% of participants taking semaglutide achieved this level of weight loss. Which one to choose ...

Tirzepatide conferred significantly greater weight loss than semaglutide at 72 weeks for adults with overweight or obesity, according to findings from the SURMOUNT-5 trial. As Healio previously ...

Tirzepatide and semaglutide are type 2 diabetes drugs that are often used for weight loss. While tirzepatide may potentially be more effective, it's too early to know that based on current research.

A three-year study of tirzepatide – a medication approved in the US as Mounjaro for diabetes and Zepbound for weight loss – found that when adults who had prediabetes and obesity or overweight ...

A new study compared the effectiveness of weight-loss drugs tirzepatide and semaglutide, finding tirzepatide leads to greater weight loss and waist reduction. Doctors shared insights.

Compounded tirzepatide contains the same active ingredient as Mounjaro, but its dosage and some ingredients may differ from Mounjaro. The Food and Drug Administration (FDA) does not regulate the ...

People taking tirzepatide injections lost more weight and were more likely to reach specific weight loss targets than those taking semaglutide, according to a new study. CNN values your feedback 1.

Tirzepatide (TZP; LY3298176) is a novel pharmacological innovation developed by Eli Lilly and Company in 2016 that combines both GLP-1 and GIP into a single subcutaneous weekly injection.